Exosomes are membrane-bound extracellular vesicles that are naturally produced and secreted by cells into the extracellular environment. These nano-sized vesicles range between 30-150nm in diameter and play an important role in intercellular communication by transferring nucleic acids, proteins and lipids between cells. Research over the past decade has revealed that exosomes have promising therapeutic applications, particularly for targeted drug delivery.
Targeted Delivery Via Exosome Therapeutics
Due to their endogenous origin and biomimetic nature, exosomes have emerged as an attractive drug delivery vehicle that can efficiently ferry therapeutic cargo such as drugs, RNAi and DNA to specific target sites and cells in the body. Exosome Therapeutics derived from stem cells or other parent cells can be loaded with therapeutic agents and used for targeted delivery. Their small size enables exosomes to overcome biological barriers and reach previously inaccessible sites in the body. Additionally, exosomes acquired membrane proteins from their parent cells, offering opportunity for active targeting through surface modifications.
Gene Therapy And Rnai Delivery
Exosomes are increasingly explored as a vehicle for non-viral gene therapy and delivery of RNA interference molecules (RNAi). Several studies have demonstrated that exosomes can effectively ferry mRNA, miRNA and siRNA into target cells and elicit therapeutic responses. For example, exosomes loaded with CRISPR-Cas9 RNA have shown gene editing activity in recipient cells. Dendritic cell derived exosomes were engineered to carry tumour siRNA and tested to reduce lung tumour growth in mice. Such studies provide proof-of-concept that exosomes may become an efficient non-viral alternative for RNA therapeutic delivery.
Clinical Potential In Cancer Immunotherapy
Cancer immunotherapy aims to harness the body's own immune system to fight cancers has emerged as one of the most promising anti-cancer strategy. Exosomes may play a key role in cancer immunotherapy approaches. Dendritic cell derived exosomes pulsed with tumour-associated antigens were shown to activate tumour specific CD4+ and CD8+ T cell responses to suppress tumour growth in preclinical studies. Ongoing clinical trials are evaluating exosomes for cancer vaccine applications. Adoptive cell therapy using exosomes from gene modified T cells is another area of active investigation for targeted cancer treatment.
Challenges And Future Prospects
While exosome research holds immense promise, several challenges remain before the full potential of exosome therapeutics can be realized in the clinic. Large scale production of exosomes with high purity, stability and efficiency remains a major obstacle. Methods to achieve targeted delivery to desired sites or cell types need further development.
More in-depth studies are still required to fully characterize safety and toxicity profiles of exosomes before human trials. With continued research, these hurdles are expected to be overcome gradually. Exosome therapeutics represents an innovative approach to develop minimally invasive, multi-functional targeted therapies. With further refinements, exosomes are positioned to revolutionize drug delivery for various pathological conditions including cancer in the coming decade.
Get more insights on this topic: https://www.zupyak.com/p/4280758/t/exosome-therapeutics-innovative-drug-delivery-method-shows-promise-in-preclinical-trials
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it